HOOKIPA Pharma to Present at Upcoming Conferences in November

NEW YORK and VIENNA, Austria, Oct. 31, 2019 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. HOOK ‘HOOKIPA'))), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, today announced its participation at two upcoming conferences in November:

  • 6th BioCentury-BayHelix China Healthcare Summit in Shanghai: HOOKIPA will present on Tuesday, November 19, 2019, at 4:15 pm China Standard Time (CST) in Ballroom II and participate in 1x1 meetings



  • Jefferies 2019 Healthcare Conference in London, November 20, 2019: HOOKIPA will participate in 1x1 meetings with investors.

Additional information will be available within the Investors & Media section of HOOKIPA's website at https://ir.hookipapharma.com/events.

About HOOKIPA

HOOKIPA Pharma Inc. HOOK is a clinical stage biopharmaceutical company developing a new class of immunotherapeutics, targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system.

HOOKIPA's proprietary arenavirus-based technologies, VaxWave®*, a replication-deficient viral vector, and TheraT®*, a replication-attenuated viral vector, are designed to induce robust antigen specific CD8+ T cells and pathogen-neutralizing antibodies. Both technologies are designed to allow for repeat administration while maintaining an immune response. TheraT® has the potential to induce CD8+ T cell response levels previously not achieved by other published immuno-therapy approaches. HOOKIPA's "off-the-shelf" viral vectors target dendritic cells in vivo to activate the immune system.

HOOKIPA's VaxWave®-based prophylactic cytomegalovirus vaccine candidate is currently in a Phase 2 clinical trial in patients awaiting kidney transplantation from living cytomegalovirus-positive donors. To expand its infectious disease portfolio, HOOKIPA has entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to jointly research and develop functional cures for HIV and Hepatitis B infections. HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. 

TheraT® and VaxWave® are not approved anywhere globally and their safety and efficacy have not been established.

Find out more about HOOKIPA online at www.hookipapharma.com.

*Registered in Europe; Pending in the US.

For further information, please contact:

Media                                                                          

Nina Waibel   

Senior Director - Communications

Nina.Waibel@HookipaPharma.com

Investors

Matt Beck

Executive Director - Investor Relations

Matthew.Beck@HookipaPharma.com

Media enquiries

Sue Charles/ Ashley Tapp

Instinctif Partners

Hookipa@Instinctif.com

+44 (0)20 7457 2020

Primary Logo

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!